Stockscreener 앱 받기
1.68
13.51%
0.20
시간 외 거래:
1.62
-0.06
-3.57%
전일 마감가:
$1.48
열려 있는:
$1.48
하루 거래량:
227.99K
Relative Volume:
2.56
시가총액:
$28.01M
수익:
$3.20M
순이익/손실:
$-10.90M
주가수익비율:
-2.4933
EPS:
-0.6738
순현금흐름:
$-7.92M
1주 성능:
+14.29%
1개월 성능:
+18.31%
6개월 성능:
-23.29%
1년 성능:
+7.01%
1일 변동 폭
$1.48
$1.72
1주일 범위
$1.4414
$1.72
52주 변동 폭
$0.8099
$4.07
마커 테라퓨틱스 Stock (MRKR) Company Profile
명칭
Marker Therapeutics Inc
전화
(713) 400-6400
주소
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.68 | 24.68M | 3.20M | -10.90M | -7.92M | -0.6738 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Canaccord Genuity | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Overweight |
| 2021-03-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-03-01 | 개시 | Janney | Buy |
| 2018-12-03 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
마커 테라퓨틱스 주식(MRKR)의 최신 뉴스
MSN Money - MSN
Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook - simplywall.st
MRKR Q1 2026 Earnings: Narrower Loss Surpasses ExpectationsRevenue Growth Outlook - dars.gov.et
US High Growth Tech Stocks to Watch - simplywall.st
Stock List: Research Stocks from Around the World - GuruFocus
Price to earnings forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
MRKR Forecast — Price Target — Prediction for 2027 - TradingView
Marker Therapeutics, Inc. Actuals & Estimates (NASDAQ:MRKR) - TradingView
Price to sales forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
Price to book forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
GX1 Forecast — Price Target — Prediction for 2027 - TradingView
Marker Therapeutics Inc (MRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Marker Therapeutics Inc (MRKR) Institutional Confidence - TradingKey
Marker Therapeutics Inc (MRKR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Marker Therapeutics Inc (MRKR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Marker Therapeutics Inc (MRKR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Marker Therapeutics Inc (MRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Marker Therapeutics Inc (MRKR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Marker Therapeutics Holds Steady Near Key Support and Resistance LevelsADD Alert - newsline.com
Marker Therapeutics Inc (MRKR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exploring 3 High Growth Tech Stocks in US Market - simplywall.st
Marker Therapeutics (MRKR) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Inches HigherEPS Growth Report - newsline.com
MRKR Q1 2026 Earnings: Narrower-than-expected loss highlights cost management amid pipeline progressGuidance vs Actual - newsline.com
Marker Therapeutics (MRKR) Holds Steady Above Support as Biotech Sector Shows Mixed SignalsHigh Dividend Factor - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Exploring High Growth Tech Stocks In The US Market - simplywall.st
MRKR Q1 2026 Earnings: Smaller-than-Expected Loss Surprises PositivelyProfit Growth Outlook - newsline.com
MRKR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNon-GAAP Earnings - dars.gov.et
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Pancreatic Cancer Clinical Trial Pipeline Gains Momentum: 170+ - openPR.com
MRKR Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentProfit Inflection Point - dars.gov.et
Mrkr Q1 2026 Earnings: EPS Beats Estimates as Company Advances PipelineFinal Results - The Legal Advocate
US High Growth Tech Stocks To Watch - simplywall.st
Marker Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Biotech Advances PipelinePre-Announcement Alert - The Legal Advocate
MRKRMarker Therapeutics Inc Stock Price and Quote - Finviz
Marker Therapeutics (MRKR) Faces Pressure: Stock Slips 2.1% to $1.4Undervalued Stocks - newsline.com
Marker Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline ProgressesMargin Compression Risk - Newser
Marker Therapeutics Inc. (MRKR) Q1 2026 Earnings: EPS Beat Expectations Amid Development Stage OperationsRevenue Estimate Trend - Newser
Marker Therapeutics Q1 2026 Earnings: Loss Narrows as Clinical Progress ContinuesPost-Earnings Drift - Newser
Marker Therapeutics (MRKR) upgraded to buy: What does it mean for the stock? - MSN
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern - Stock Titan
Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) — 10-Q Summary - TradingView
MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027 - TradingView
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
마커 테라퓨틱스 (MRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):